Clinical Trial Eligibility in China: Screening Explained

Understand trial pre-screening, inclusion and exclusion criteria, biomarker and washout checks, screen failure, open slots and international-patient barriers.

Key takeaways

A registry match is a pre-screen at most. Only the study investigator confirms eligibility, working from source records and protocol-required tests after the consent process.
Eligibility rules exist to protect participants and to define the population that can answer the research question. Nobody is judging whether a patient “deserves” treatment.
Diagnosis, biomarker, prior therapy, washout, performance status, organ function, infection risk, the practical ability to follow the protocol — any of these can decide the outcome.
Screen failure comes in several kinds: permanent, temporary, medical, operational. Ask which exact criterion stopped you, and whether repeat testing or another cohort is possible.
A patient can be fully eligible and still get no open slot, no allocation and no benefit from the investigational treatment.

Full guide

Eligibility for a clinical trial sounds like a yes-or-no question. On the ground it works more like a series of gates. Someone can look suitable on a one-page summary, get through the coordinator’s pre-screen, and then fall short on a single laboratory threshold or the central pathology review. Someone else satisfies every medical criterion and still gets turned away because the cohort has stopped recruiting.

ClinicalTrials.gov describes eligibility criteria as the inclusion requirements a participant must meet plus the exclusion characteristics that block participation [1]. The public listing is a good search tool. The final word, though, sits with the approved protocol — a website summary, a referral letter or a commercial matching report all take a back seat to it.

Four decisions that should not be confused

Potential match: diagnosis, stage, age and a handful of major features look compatible with a public listing.
Pre-screened candidate: a site coordinator or investigator has seen enough records to justify formal screening.
Protocol eligible: the investigator has verified each applicable criterion against the required documents and tests, all inside the specified windows.
Enrolled or allocated: a suitable cohort and slot are open, consent and registration are done, and any randomisation or assignment has happened.

“Likely eligible” at gate one or two is still a long way from gate four. NCI describes pre-screening as an initial discussion, while screening is the more thorough review of history and tests that happens around the consent process [2].

Why trials use inclusion and exclusion criteria

Criteria do two jobs at once. First, they cap foreseeable risk — a drug cleared through the liver, say, may be too toxic for someone with severe liver dysfunction. Second, they assemble a population in which the scientific question can actually be interpreted. A trial testing a targeted drug only in tumours carrying a particular alteration would be answering a different question if it enrolled tumours without that alteration.

NCI lists health, treatment history and tumour genetic changes among the common criteria, and notes that a more comparable study population reduces confounding [3]. Narrow criteria cause problems too, and regulators and researchers have pushed for broader, scientifically justified eligibility — including more thoughtful inclusion of people with organ dysfunction, prior cancers or brain metastases [4,5]. That trend, however generous, never overrides the wording of an individual active protocol.

What the protocol may check

Each study writes its own list; oncology screening typically covers:

Disease identity: pathology type, primary site, stage, whether the disease is measurable or evaluable, and evidence of progression or relapse.
Biology: the named mutation, fusion, amplification, protein expression or other biomarker — sometimes with confirmation by a designated central laboratory.
Treatment history: prior lines that are required or prohibited, response or resistance, radiation fields, transplant, cell therapy, cumulative drug exposure and toxicities that have not resolved.
Timing: washout from chemotherapy, immunotherapy, radiotherapy, surgery or another trial, plus recovery from an acute procedure or adverse effect.
General condition: performance status, expected survival, nutrition, and the ability to complete the visits and procedures.
Organ function: blood counts and liver, kidney, coagulation, cardiac or pulmonary measures as defined by the protocol.
Comorbidity and infection: active infection, immune disease, seizures, brain metastases, another malignancy, or conditions that could raise risk or muddy the outcomes.
Concomitant treatment: steroids, anticoagulants, antiarrhythmics, strong metabolic inhibitors or inducers, supplements, live vaccines and any prohibited anticancer therapy.
Reproductive safety: pregnancy and breastfeeding status, pregnancy testing, contraception, and restrictions on sperm or egg donation.
Operational requirements: research biopsies, frequent blood draws, electronic diaries, consent in a supported language, reliable follow-up and access to urgent care.

Wording matters here. Phrases like “prior platinum,” “stable brain metastases,” “adequate archival tissue” and “recovered to Grade 1” each carry a protocol definition. A discharge summary that says only “chemotherapy completed” establishes neither the drug, the dose, the dates nor the response.

What to prepare for a credible pre-screen

Build the file so it reads chronologically and every item can be verified. That means the pathology report; the molecular report with specimen identifier, method and date; treatment names, doses and start/stop dates; operative and radiotherapy summaries; recent imaging reports — ideally the original DICOM files; the current medication list; major comorbidities; recent laboratory results; and any adverse effects that have not resolved.

Before sending anything, ask which documents need certified translation and whether the site wants tumour blocks, unstained slides or newly collected tissue. When the protocol specifies tissue, a blood-based biomarker result will not necessarily substitute; a local positive result can still require central confirmation.

One caution: never stop effective standard treatment or begin a washout just because an online service reports a match. The trial investigator and the treating clinician need to weigh urgency, alternatives and the risk of delay first.

Consent and formal screening

Procedures done purely for research generally wait until an approved informed-consent process is complete. Screening can then involve an examination, repeat laboratory tests, pregnancy testing, ECG or echocardiography, imaging, infection testing, pathology review and biomarker confirmation. Each result carries a validity window — a test run too early may have to be repeated.

Under China’s current 2020 Good Clinical Practice rules, ethics review and informed consent are mandatory, investigators must follow the approved protocol, and participant rights and safety come ahead of scientific and social benefit [6]. A revised drug GCP came out in June 2026 and is scheduled to take effect on 1 September 2026 [7]. Anyone whose screening straddles that changeover should ask the site which ethics-approved documents apply.

Why a result may change between pre-screen and screening

Eligibility can hinge on how the patient happens to be doing on a given day. Neutrophils recover after treatment. Liver tests worsen. A fresh scan turns up a lesion nobody knew about. The central laboratory reads a biomarker differently, or a prohibited medicine turns out to need a longer washout. Sites also sometimes find that a prior regimen misses the protocol’s exact definition of that line of therapy.

Screenshots and verbal assurances count for little here. Ask the coordinator to name the criterion at issue, the source document behind it, and the date by which any time-sensitive measurement has to be repeated.

Four kinds of screen failure

Permanent biological mismatch: the tumour type is wrong, the required alteration is absent, or a prohibited treatment history cannot change.
Temporary timing or recovery issue: the washout is incomplete, blood counts are still recovering, an infection is under treatment, or a short-term medication conflicts. Rescreening may be possible only if the protocol allows it.
Medical safety issue: organ function, comorbidity or instability pushes the expected risk past what is acceptable.
Operational failure: no open slot, a closed cohort, inadequate tissue, a required assessment unavailable, or a visit schedule the patient cannot meet.

Each category calls for a different next step. A temporary issue can clear with time; an operational failure says nothing about whether the treatment suits the patient medically. On the other hand, no amount of repeat testing fixes a permanent biological mismatch.

Can the centre make an exception?

An investigator cannot quietly drop a criterion because a patient travelled a long way or has run out of alternatives. Departures put safety at risk and undermine the trial’s data. When the wording is ambiguous, the investigator can request a documented interpretation from the sponsor or medical monitor. Genuinely changing a criterion normally takes a protocol amendment plus ethics or regulatory review — a private exception is not how it happens.

ICH E6(R3) makes the same point: a well-designed protocol is fundamental to participant protection and reliable results [8]. Patients may ask for an explanation and request a second review when records are missing. Anyone who promises to “guarantee” qualification deserves suspicion.

Additional barriers for international patients

Before booking travel, pin down the exact recruiting site and cohort — a global “recruiting” status can hide a closed local cohort. Then ask: who reviews the translated source records? Can tissue be exported, and will the laboratory receive it? How long does central testing take? Do local residency, insurance or payment arrangements apply? How many days must the patient stay nearby? And once the patient is home again, who manages fever, bleeding or other emergencies?

The same conversation should cover interpreter availability, the split between research and routine-care costs, companion expenses, visa timing and telehealth limitations, plus whether protocol follow-up can happen abroad. A person can be medically eligible and still unable to enroll, if mandatory visits or emergency coverage cannot be delivered safely.

Questions worth sending to the study site

Is the cohort for my exact disease or biomarker open at this location today?
Which criteria can you assess from records, and which require on-site tests?
Who makes the final eligibility decision, and is central pathology or imaging review required?
How long are the washout and screening windows, and should my current treatment continue in the meantime?
If screening fails, will the site tell me the criterion, whether it is temporary, and whether rescreening is allowed?
Does eligibility guarantee a slot, or is there a waitlist or competitive enrollment?
What standard-treatment options could be lost or delayed during screening?

Eligibility settles one question only: whether the protocol permits participation. It says nothing about whether the investigational treatment beats standard care, whether the patient will land in the experimental arm, or whether the tumour will respond.

Medical disclaimer: This guide is educational and cannot determine anyone’s eligibility. Applying the current protocol to complete source records and screening results is the authorised study investigator’s job alone. Never delay urgent care while pursuing a trial.

FAQ

If I match every criterion shown on ClinicalTrials.gov, am I eligible?

Not yet. The listing only supports pre-screening. The site still has to apply the full current protocol, verify the source documents and complete the required testing — and the relevant cohort has to be open.

Can an abnormal laboratory result be repeated?

Sometimes. The protocol spells out acceptable windows, repeat testing and rescreening. A transient abnormality may improve on its own, but no one should manipulate a result with unapproved treatment just to cross a threshold.

Can paying privately reserve a clinical-trial place?

Money does not substitute for eligibility, ethics review or cohort availability. A legitimate research site explains ordinary-care costs and research costs separately, and it will never sell a guaranteed place.